When a friend’s child had a rare neurological disorder recently, Michael J. Misialek, MD, a pathologist at Newton-Wellesley Hospital in Massachusetts, was asked about the diagnostic value of a lab test. The cost of this complex molecular test was $15,000, and the child had already had the test twice on the advice of a pediatric neurologist.
Misialek found himself in the uncomfortable position of having to tell his friend that the test was not appropriate and that other tests might be more useful given the child’s condition. As Misialek and others have written, clinical laboratory testing is a complex endeavor, and physicians do not always order the proper tests for their patients.
The growing number and complexity of tests available today contribute to the problem, he says. For this particular patient, there was little Misialek could do, but as a pathologist in a major metropolitan health system, he knows the problem of increased lab test utilization and inappropriate ordering all too well.
Pathologists can identify the right test for the right patient at the right time, says Michael J. Misialek, MD, at Newton-Wellesley Hospital in Massachusetts. Pathologists interact with many specialists.
Kim Riddell, MD, a pathologist and section chief in the clinical laboratory at Group Health Cooperative in Seattle, also is concerned about the rising number of test orders coming through her department and wants to ensure that all testing is appropriate. As chairwoman of the laboratory utilization management committee, she oversaw an evaluation in 2003 that compared the number of tests Group Health was running against that of other clinical labs in the area. The results were surprising.
“Our unit costs were just about in line with that of the other labs, but we were surprised to see that our utilization was much higher than everyone else in Washington state,” she says. “The study showed our physicians seeing outpatients were ordering more tests than anyone else.
“Even though these patients didn’t have any complaints, they were automatically getting a urinalysis, chemistry panels, a thyroid-stimulating hormone [TSH] test, and a complete blood count [CBC].”
Such testing for well-visit patients is wasteful, Riddell says. “They don’t uncover much of anything and yet they lead to more testing or needless referrals to specialists. They were ordering these tests just out of habit.”
The results of the evaluation led Riddell to start a lab-test utilization management (UM) effort that may be one of the longest running and most comprehensive lab UM programs among health plans in the nation.
As Riddell learned in the evaluation, clinical laboratory testing often goes unmanaged in part because it consumes only an estimated 3% to 4% of health care dollars. Yet lab test volume is rising as the aging population demands more testing and physicians run tests to identify disease early. And labs are introducing more expensive genetic and molecular tests, driving utilization and costs.
In June, the Medicare Payment Advisory Commission (MedPAC), which advises Congress, said spending for services to Medicare patients in all clinical lab settings increased by 9.1% in 2012. The MedPAC report, A Data Book: Health Care Spending and the Medicare Program, said spending for clinical laboratory services grew by an average of 5.6% annually.
Medicare is usually a bellwether of what goes on in the insurance industry, and its recent experience with laboratory testing costs gives pause. In 2012, spending for services in all clinical laboratories increased by 9.1%. From 2003 through 2012, a rising number of clinical laboratory tests pushed up Medicare spending for clinical laboratory services by an average of 5.6%.
Medicare spending for clinical laboratory services, 2003–2012 (billions)
Source: A Data Book: Health Care Spending and the Medicare Program, Medicare Payment Advisory Commission, June 2014
“This growth was primarily driven by rising volume since there were only three increases in lab payment rates during those years (1.1% in 2003, 4.5% in 2009, and 0.65% in 2012). Yet clinical lab services accounted for only 1.7% of total Medicare spending in 2012,” MedPAC said in the report.
Health plans know that sharply rising cost increases are unsustainable and that such growth in utilization may indicate needless overtesting.
One of the nation’s largest health plans reported last year that laboratory testing costs were rising at twice the rate of overall medical costs and, as Group Health and MedPAC found, unit costs were not the big factor. Instead, lab test utilization was rising.
While overall medical costs were rising at 4% to 5% annually, spending for outpatient clinical lab services was climbing by 8% to 10% annually, and two thirds of the increase in laboratory spending came from increases in utilization, a plan official said. For this plan, lab test costs were only about 5% of the plan’s total medical spending.
After analyzing the data, the plan found that, just as Group Health learned, the unit costs were not rising sharply. But use of molecular diagnostic testing was rising at about 20% to 30% every year and testing to support therapeutic drug decisions was rising at 50% annually and at 200% in a recent three-year span, the plan reported.
While most health plans do not report lab test utilization, it is likely that all plans are seeing similar trends and are adopting strategies such as laboratory UM, as Group Health has done since 2003. UnitedHealthcare (UHC) is introducing an extensive laboratory benefit management program for its commercial members in Florida.
Essentially, UHC is installing a benefit management system for laboratory testing. Just as CVS/Caremark and Medco manage pharmacy benefits for health plans and employers, Beacon Laboratory Benefit Solutions (BeaconLBS), a division of Laboratory Corp. of America, will manage UHC’s lab test utilization in Florida.
BeaconLBS includes a decision support tool that physicians serving UHC’s commercial members must use when ordering any of dozens of tests that UHC lists on its Web site. The decision support tool requires physicians to give UHC advance notification when ordering these tests.
Among the tests requiring decision support are BRCA1 and BRCA2 for breast cancer. Both require prior authorization. The program also includes a network of preferred laboratories in Florida.
UHC will not pay for tests ordered by physicians who fail to meet UHC’s lab testing requirements.
UHC said, “BeaconLBS identifies for physicians and their patients high quality, accredited laboratories, and uses evidence-based clinical guidelines to improve quality and appropriate utilization of laboratory services. By making it easier to share information between physicians, labs, and health plans, BeaconLBS is helping to lower the cost of care while improving the coordination and quality of a patient’s laboratory services.”
Evidence-based testing is the key to Riddell’s UM program at Group Health. “In the literature, there are very few recommendations for routine testing, and most of those are tests for children. Adults who are well should get are a cholesterol or lipid panel, but no more than once a year,” says Riddell. Other recommended tests are chlamydia, stool occult blood tests, one-time hepatitis C virus test for certain age classes, PAP smears, and a PSA test only with shared decision making. “But that’s it.”
Standing orders built into electronic health record systems also drive up the use of clinical lab tests, Riddell says. “Why does a patient need a serum protein electrophoresis every two weeks? That’s an electronic standing order, and yet it’s just not necessary to do that every two weeks for every patient. For some patients, certainly, but not for all, and not at that frequency.”
Testing at routine visits can be wasteful, says Kim Riddell, MD, of Group Health Cooperative. “They don’t uncover much of anything” but can lead to more tests.
Riddell rejects arguments from physicians that routine testing has low cost and helps to identify disease early. “It’s not so much the cost of the test itself; the downstream effects on the health care system are expensive as a consequence of testing. Testing leads to more testing, especially if there are false positives. It creates needless costs because any abnormal value needs more testing and perhaps a referral to a specialist. Maybe the patient has to return to have more blood drawn. It creates unnecessary noise without improving the quality of care,” she says.
To manage utilization, Riddell developed a report card for each family physician showing who orders tests inappropriately. “We knew we couldn’t just send them reminders or a newsletter,” she says. “Only a few will read it and, if they do make changes, the change won’t last. You need something definitive to show their performance exactly.”
By enlisting help of the information technology department, Riddell focused on the most-ordered tests. “IT gave us a tool that allowed us to see the top 25 physicians ordering any test you could name for any period of time. We targeted the chemistry panels, the thyroid stimulating hormone (TSH), and the complete blood count (CBC), basically anything associated with wellness. Then we did a deeper dive to see how many of these were ordered and by whom.”
Over the course of a year, lab staff met with physician leaders throughout Group Health’s system, explaining how the report card would work and how it would list all family physicians by name and show their lab test usage. That meant any physician could see how any doctor’s scores compared to his or her group, the region, or the entire health plan.
“Just by creating awareness about the overuse of testing, we saw a drop in utilization,” Riddell says. “Then when the report cards came out, we saw another drop in utilization because a lot of physicians quit ordering inappropriate tests entirely. Still, we had some outliers. So we sent them reminder post cards and then we saw another drop in ordering.”
In particular, Group Health wanted to cut the use of CBCs and TSHs for well-patient visits by half and wanted to eliminate the use of a panel of 14 chemistry tests that physicians were ordering regularly. Riddell reports that from 2003 to the fourth quarter of 2014, tests per 100 well visits dropped from 2.5 to 0.43 for the 14 chemistry tests; 2.5 to 0.91 for CBCs; and 1.7 to 0.3 for TSH.
Since then, decreased ordering has become the norm except when new physicians are hired or during one quarter in 2011 when the IT department could not support the program, she adds. As soon as the IT department got back to producing the reports, usage dropped again.
“When we see a blip because a new physician comes in, we send that physician a letter and copy the medical chief in the practice. Then, the problem disappears,” she says.
Routine testing is just one part of lab test utilization management, however. Health plans, hospitals, and health systems also are focusing on high cost molecular and genetic testing. “There’s a whole universe of strategies for laboratory utilization management, and routine tests are just one small part,” Riddell says.
Gene-based testing may make up about one third of all diagnostic tests, according to InformedDNA, a company that provides genetic counselors to members of Cigna and other health insurers. Use of these tests is expected to rise sharply. A UHC report in March 2012, “Personalized Medicine: Trends and Prospects for the New Science of Genetic Testing and Molecular Diagnostics,” estimated that annual spending on genetic tests totaled more than $5 billion in 2010 and could reach $25 billion in 10 years.
When ordering these tests, specialist physicians at Group Health are required to follow guidelines. “To be done correctly, high-cost testing needs to be integrated with other testing,” Riddell says. “When BRCA testing for breast cancer started to pick up, we said only a medical geneticist could order a BRCA test and only after the patient had an evaluation.”
Last year, Cigna required patients considering tests for certain genetic abnormalities to meet with genetic counselors, and other health plans are likely to do the same, says Joy Larsen Haidle, president of the National Society of Genetic Counselors.
“Health insurers are falling in line with what Cigna is doing,” she says. “Some regional plans require their members to see a genetic counselor before making a determination on a given test.”
“Research shows that ... 30% of all genetic tests that physicians order are inappropriate or unnecessary,” says Joy Larsen Haidle, president of the National Society of Genetic Counselors.
A genetic counselor will assess a patient’s risk and appropriateness for genetic testing. Such assessments are needed because physicians often do not know which genetic tests are most appropriate for which patients, she adds.
“Research shows that about 30% of all genetic tests that physicians order are inappropriate or unnecessary,” Larsen Haidle says. “When the average gene test costs about $2,000 per gene, that’s a lot of money.”
Errors in ordering are common because patients and physicians are unfamiliar with most genetic tests, Larsen Haidle adds.
After Priority Health, an insurer in Michigan, estimated that 30% of genetic tests were ordered incorrectly, the health plan had genetic counselors work with patients and ordering physicians to ensure that the proper genetic tests were ordered. Priority Health estimated the savings at $7.2 million in one year, Larsen Haidle says.
Such errors demonstrate the need for close scrutiny of lab test orders. “There is a trend toward using genetic counselors in the utilization management role either at the diagnostic laboratory or at the send-out laboratory at the referring institution,” says Larsen Haidle.
“We want to know if the right test was selected. Is it the correct gene for the abnormality in question, and is this person an appropriate candidate for this test?”
Misialek says that the pathologist’s role is to identify the right test for the right patient at the right time. “Pathologists have a unique role in health care because they are at the interface of multiple specialties, including primary care; care in the hospital; and care throughout the entire health care system,” he says.
“In addition, something like 70% to 80% of the information in a medical record is laboratory data. No one would treat a patient in a hospital without lab data.
“Therefore,” Misialek continues, “we may be able to realize significant savings by managing routine daily tests such as the low-cost CBCs and chemistry panels. If we can eliminate that one lab draw in the morning and multiply that by 300 to 500 patients in each hospital and in the thousands of hospitals nationwide, that could add up to significant savings.”
Riddell made similar comments, saying that close scrutiny is required of as many lab test orders as possible, particularly high-cost tests and tests for which orders are rising sharply.
“Utilization management involves everything, the common tests, the expensive tests, and the highly unusual tests. It also involves educating physicians and the public about the importance of following evidence-based decision making whenever it is possible.”